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Abstract
Background: Chalmers and Glasziou’s paper published in 2014 recommends research funding bodies should
mandate that proposals for additional primary research are built on systematic reviews of existing evidence
showing what is already known. Jones et al. identified 11 (23 %) of 48 trials funded during 2006–8 by the National
Institute for Health Research Health Technology Assessment (NIHR HTA) Programme did not reference a systematic
review. This study did not explore the reasons for trials not referencing a systematic review or consider trials using
any other evidence in the absence of a systematic review. Referencing a systematic review may not be possible in
certain circumstances, for instance if the systematic review does not address the question being proposed in the
trial. The current study extended Jones’ study by exploring the reasons for why trials did not reference a systematic
review and included a more recent cohort of trials funded in 2013 to determine if there were any changes in the
referencing or use of systematic reviews.
Methods: Two cohorts of NIHR HTA randomised controlled trials were included. Cohort I included the same trials
as Jones et al. (with the exception of one trial which was discontinued). Cohort II included NIHR HTA trials funded
in 2013. Data extraction was undertaken independently by two reviewers using full applications and trial protocols.
Descriptive statistics was used and no formal statistical analyses were conducted.
Results: Five (11 %) trials of the 47 funded during 2006–2008 did not reference a systematic review. These 5 trials had
warranted reasons for not referencing systematic reviews. All trials from Cohort II referenced a systematic review. A quarter
of all those trials with a preceding systematic review used a different primary outcome than those stated in the reviews.
Conclusions: The NIHR requires that proposals for new primary research are justified by existing evidence and the findings
of this study confirm the adherence to this requirement with a high rate of applications using systematic reviews.
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Background
The use of systematic reviews to identify gaps in health
related research is well documented and should be con-
ducted, with or without a meta analyses, to assess exist-
ing evidence and the need for further primary research
[1]. Chalmers and Glasziou’s paper on how to increase
value and reduce waste when research priorities are set
identified from surveys of previous reports of clinical
trials that existing research was being ignored. The
study identified from an analysis of 50 reports including
more than 1500 cumulative meta-analyses of clinical
intervention studies that if researchers had systematic-
ally assessed what was already known some beneficial
and harmful effects of treatments could have been
identified earlier. In these cases systematic reviews
would have reduced waste resulting from unjustified
research. The authors provided a number of recom-
mendations for research funders, most notably that
proposals for additional primary research are justified
by systematic reviews showing what is already known
* Correspondence: S.D.Bhurke@southampton.ac.uk
1Wessex Institute, University of Southampton Alpha House, University of
Southampton Science Park, Southampton SO16 7NS, UK
2National Institute for Health Research (NIHR), Evaluation, Trials and Studies
Coordinating Centre (NETSCC), University of Southampton, Southampton
SO16 7NS, UK
Full list of author information is available at the end of the article
© 2015 Bhurke et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Bhurke et al. BMC Medical Research Methodology  (2015) 15:108 
DOI 10.1186/s12874-015-0102-2
[2]. If new research is needed it should be justifiable
both scientifically and ethically and needs to be
planned in the context of an assessment of relevant
previous research, ideally through a systematic review
[3, 4]. As such, efforts should be taken to understand
and improve the production of research in its
entirety.
Systematic reviews provide a synthesis of evidence for
practitioners, for clinical practice guideline developers,
and for those designing and justifying primary research.
It is therefore important to have an up-to-date review.
However, previous work by Clarke and Hopewell has
shown that very few investigators state that they had
used up-to-date systematic reviews when designing their
new clinical trials [5]. Further research has shown the
extent of the lack of use of systematic reviews in plan-
ning the targeted sample size calculations [6] as well as
the design of the interventions [7].
In 2013, Jones et al. investigated the use of systematic
reviews in the planning, design and conduct of rando-
mised trials funded by the NIHR HTA Programme
during 2006, 2007 and 2008 [8]. Although the study pre-
dates the Chalmers and Glasziou 2009 Lancet publica-
tion, the findings provide a useful insight to the clinical
relevance of the research question and appropriateness
of the trial design. The study concluded that 37 HTA ap-
plications (77 %) out of 48 referenced a systematic re-
view and 20 of these 37 applications (54 %) reported the
use of systematic reviews in the trial design [8]. Eleven
(23 %) out of the 48 applications made no reference to
systematic reviews and of these 7 (15 %) stated that
there had been no previous trials and one explicitly
stated the absence of a systematic review. The reasons
for why these trials did not reference a systematic review
was however was absent from Jones et al. study. The
paper did not consider that in the absence of a system-
atic review there might have been other evidence con-
firming the rationale for the trial. Since only half of trials
assessed in Jones et al. used a systematic review to in-
form the trial design, the current study chose to investi-
gate this issue further. The purpose of our study was to
firstly replicate the Jones et al. study and secondly ex-
plore, a. the reasons why some trials did not reference a
systematic review, b. provide a classification system for
inclusion and c. extend and include a more recent co-
hort of NIHR HTA-funded trials (2013) post Chalmers
and Glasziou 2009 Lancet publication to determine any
improvements over time.
Methods
Two cohorts of randomised controlled trials funded
by the NIHR HTA Programme were used. The first
cohort included the same NIHR HTA trials funded in
2006, 2007 and 2008 as that of Jones et al. [8] (with
the exception of one trial which was discontinued in
2009 due to problems with recruitment). We ex-
tended Jones et al’s analysis by exploring the reasons
why some trials did not reference a systematic review.
The second cohort included NIHR HTA trials funded
in 2013 to explore whether changes made by the
HTA programme towards the content of the applica-
tions, has had an impact on how systematic reviews
are used to inform trial design. The funding process
for NIHR HTA trials comprises several stages (Fig. 1).
Researchers can apply for funding for their own re-
search idea through the researcher-led workstream or
through the commissioned workstream whereby re-
searchers apply for funding in response to an adver-
tised brief in areas identified as important to the
NHS by the HTA prioritisation panel.
The list of relevant HTA trials funded during the
periods 2006 to 2008 and 2013 were identified by the
HTA funding team senior programme manager. We
had full access to the relevant documentation, includ-
ing outline, full application, protocol, board minutes
and comments from experts. The protocols for all in-
cluded studies were publicly available and the
remaining documents we used can be obtained by
bona-fide researchers on application. From both the
cohorts, studies that have been published were freely
available but for the studies that were still in the edi-
torial process, we accessed the final draft reports. The
full application and the most current trial protocol
were predominately used as the main source of infor-
mation, unless otherwise stated.
An Access database was developed and designed for
the purposes of the project (AY). This was piloted
and amended where necessary (SB and AT). The data
extraction form was developed based on Jones et al.
[8] to include data on whether systematic reviews
were referenced and used in the design of trials for
justification of treatment comparison, choice of fre-
quency or dose, selection of an outcome, withdrawals
or adverse events etc (refer to Jones et al. for a full
listing). We developed the criteria for use of system-
atic reviews to inform the trial design (see Additional
file 1). Data extraction was independently undertaken
by two reviewers (SB and AT) and any disagreements
were resolved by discussion with a third reviewer
(AC). In the absence of reference to a systematic re-
view we explored whether additional evidence was
used to support the rationale for conducting primary
research either from the application or from the
commissioning brief if the study was funded through
the commissioning workstream.
We defined a systematic review as previously existing
if we found, relating to the trial research question, one
or more of the following:
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 a Cochrane systematic review
 other reviews if systematic review was mentioned in
the title and methods stated a systematic search was
conducted
 a National Institute for Health and Care Excellence
(NICE) Technology Appraisal Guidance (TA) which
include the Technology Assessment Report (TAR)
based on the review of clinical and economic
evidence
All data were descriptive and no formal statistical ana-
lyses were conducted. Data were stored and reported
using Microsoft Excel 2010.
Results
We included 47 trials funded by the NIHR HTA
Programme in 2006, 2007 and 2008 in the first cohort.
Of these 27 were from the commissioned and 20 from
the researcher-led workstream (see Fig. 2).
The second cohort included 34 trials funded in 2013,
of which 20 were from the commissioned and 14 from
the researcher led workstream (see Fig. 3).
Five trials from Cohort I did not reference or use a sys-
tematic review to inform their design (Table 1). All trials
from Cohort II referenced a systematic review. Additional
file 2 lists the five trials from Cohort I and the reasons
why they did not reference a systematic review.
2006-2008 - Cohort I
This cohort comprised of the same 47 NIHR HTA-
funded trials that Jones et al. included in their study with
the exception of one trial which has been discontinued
since Jones et al. published their study. Of these 42
(89 %) trials used a systematic review to inform their
Fig. 1 Funding process for the NIHR HTA programme
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design and of these 30 trials (71 %) referenced more
than one systematic review, with a total of 109 system-
atic reviews being referenced. Twenty seven (25 %) of
these 109 systematic reviews had been published in the
Cochrane Database of Systematic Review (CDSR) and
the remaining 82 (75 %) in other peer reviewed journals.
Trials reporting no systematic review
The five trials that did not use a systematic review to in-
form their design were all from the researcher-led work-
stream. For two of these trials, NICE TAs (always
informed by a systematic review) relating to that specific
drug or intervention had been published before the
funding of the HTA trial. The assumption is that the
HTA funding board would have discussed the evidence
relating to the specific drug before the HTA trial was
funded. Also, the HTA programme always runs updated
searches before the proposal is presented at the funding
board to ensure no recent research has been missed or
emergence of new evidence may influence the funding
decision. For the HTA trial PERSEPHONE (06/303/98)
shortlisted for the HTA funding board in 2006, the
NICE TA No. 34 (2002) reported the evidence for the ef-
fectiveness of trastuzumab monotherapy to be limited
and that there was insufficient evidence on the length of
follow-up [9]. The evidence for NICE TA No. 34 was
prepared by the NHS Centre for Reviews and Dissemin-
ation. In addition, a HTA systematic review (Lewis
2002), investigating the clinical effectiveness of trastuzu-
mab for breast cancer also suggested further research to
evaluate the optimum duration of the therapy [10]. For
the HTA trial TRAPEZE (06/303/205) shortlisted for the
HTA funding board in 2006, the NICE TA No. 101 pub-
lished in June 2006 identified a need for research to as-
sess the quality of life associated with different
treatments for hormone-refractory metastatic prostate
cancer using generic quality of life instruments that are
suitable for the purposes of cost-effectiveness analyses
[11]. The report also identified a need for research on
the effects of docetaxel over a longer follow-up period,
and in patient group that is more representative of a
wider patient population in terms of age, performance
status and comorbidity. The evidence to support the
NICE TA No. 101 was prepared by the Systematic Re-
views Centre for Reviews and Dissemination [12].
In the HTA trial AESOPS (06/304/142) the applicants
identified five systematic reviews but these did not cover
older patients. The five systematic reviews identified fo-
cussed specifically on the effectiveness of brief interven-
tions in primary care populations.
A systematic review may have been underway when
the HTA trial (06/403/90) of protease inhibitor mono-
therapy versus continuing combination antiretroviral
therapy for HIV-1 infected patients was funded. This
study is currently being edited for publication by the
NIHR Journals Library and has cited a systematic review
published in 2011 [13].
The HTA CHAMP trial (07/01/26) was the first large
scale trial of cognitive behaviour therapy for health anx-
iety in secondary care. The application states that there
were increasing studies on the clinical benefits of this
treatment in primary care but the added value of this
57 application & supporting documents 
available for HTA trials funded during 
2006-2008
Records screened to include RCTs of 
interventions
(n = 57) 
Excluded (n = 10) 
Diagnostic accuracy trials (n =3) 
Follow-up study (n = 3) 
Cohort (n =3) 
Discontinued (n=1)
Total included studies 
(n = 47) 
Commissioned (n = 27) 
Researcher-led (n =20) 
Fig. 2 Cohort I – HTA trials funded during 2006–2008
60 applications & supporting 
documents available for NIHR HTA 
trials funded during 2013 identified 
Records screened to include RCTs of 
interventions (n = 36) 
Excluded
Diagnostic accuracy trials (n =2) 
Total included studies (n = 34) 
Commissioned (n = 20) 
Researcher-led (n =14) 
Fig. 3 Cohort II – HTA trials funded during 2013
Table 1 Trials with no reference or use of systematic reviews
Total number
of trials
No. of trials not referencing
or using a systematic
review to inform their design
Justified reasons for not
referencing and using a
systematic review to
inform the trial design (n)
47 – Cohort I 5 5
34 – Cohort II 0 0
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treatment in secondary care in terms of cost-
effectiveness was uncertain with no evidence on the im-
portance of 2 year follow-up. This study was the first-in-
class (Additional file 3).
Trials reporting the use of a systematic review
Of the trials (n = 42) that reported using a systematic re-
view in the design or planning stages, 30 trials referenced
more than one systematic review. Therefore more than
one reason has been included in the assessment (Table 2).
We identified the use of systematic reviews in 40 out of 42
trials from the full application and trial protocol. The
remaining two trials, (07/36/01 – A randomised con-
trolled trial (RCT) of alternative treatments to Inhibit
VEGF in patients with Age-related choroidal Neovascular-
isation (IVAN) and 07/39/01 - Amnioinfusion in preterm
premature rupture of membranes (AMIPROM): a rando-
mised controlled trial of amnioinfusion versus expectant
management in very early preterm premature rupture of
membranes - a pilot study), were funded through the
commissioned workstream, which means the HTA
programme would have completed a robust search to
identify the evidence gap and determined the value of any
systematic review towards the justification of treatment.
Taking each of these trials in turn, the applicants of the
HTA trial 07/36/01 stated that they searched the literature
but found no previous trials or reviews. We independently
reviewed the background to this trial and found that the
drug in question had never been subject to a randomised
trial for the specified condition. This trial was the first-
in-class (Additional file 3).
For HTA trial 07/39/01, the applicants state the vari-
ous observational comparative studies they identified
and also discuss about a very small randomised trial of
19 women. The applicants state that further research
was recommended by NICE. Clinical guidance issued by
NICE are based upon a comprehensive literature review
including a systematic review and various clinical and
stakeholder consultations. Research recommendations,
which form part of the clinical guidance documents, are
made based on a recognised evidence gap in that area.
Primary outcomes
Fourteen (33 %) trials out of 42 that referenced a sys-
tematic review used a different primary outcome to that
used in the review. The reasons for using a different pri-
mary outcome were that the outcome was not consid-
ered clinically important, a specific primary outcome
was requested by the HTA commissioning board or be-
cause there were heterogeneous primary outcomes in-
cluded in the systematic review (Table 3).
In addition to these 14 trials, two trials used a different
primary outcome due to the multiplicity of reviews with
varying primary outcomes. Therefore it was unclear
which review informed the primary outcome.
2013 – Cohort II
This cohort included 34 NIHR HTA trials funded during
2013. All trials referenced and used a systematic review
to inform the trial design. Of these 20 (59 %) referenced
more than one systematic review, with 80 systematic re-
views referenced in total. Sixteen (20 %) of these 80 sys-
tematic reviews had been published in the CDSR and
the remaining 64 (80 %) published in other peer
reviewed journals.
Trials reporting the use of a systematic review
Of all the 34 trials reporting the use of a systematic re-
view in the design or planning of a trial, 20 referenced
more than one systematic review. Therefore more than
one reason has been included and Table 2 summarises
these reasons. We identified the use of systematic
Table 2 The use of systematic reviews in trial design
Reasons Cohort I No. of
applications (%)
Cohort II No. of
applications (%)
(n = 42) (n = 34)
Adverse events 7 (16.6) 1 (2.9)
Choice of frequency/dose 2 (4.7) 1 (2.9)
Duration of follow-up 1 (2.3) 2 (5.8)
Estimating the control
group event rate
2 (4.7) 0 (0)
Estimating the difference
to detect or margin of equivalence
2 (4.7) 1 (2.9)
Inform standard deviation 0 (0) 3 (8.8)
Intensity of interventions 1 (2.3) 1 (2.9)
Justification of prevalence 3 (7.1) 0 (0)
Justification of treatment comparison 38 (90.4) 32 (94.1)
Recruitment and consent 4 (9.5) 1 (2.9)
Route of intervention 0 (0) 1 (2.9)
Selection of definition or outcome 5 (11.9) 5 (16.1)
Withdrawal rate 1 (2.3) 0 (0)
Table 3 Reasons for using different primary outcome
Reasons Cohort I No. of
applications (%)
Cohort II No. of
applications (%)
(n = 14) (n = 8)
Change requested by HTA
commissioning board
2 (14.2) 0 (0)
Feasibility/Pilot Study 2 (25) 0 (0)
Heterogeneous outcomes in the
review
1 (7.1) 0 (0)
Primary outcome not believed
to be clinically important
11 (78.5) 2 (25)
Unclear 0 (0) 4 (50)
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reviews in 32 out of 34 trials from the full application
and trial protocol. The first remaining trial (11/148/01)
was funded through the HTA commissioned workstream
which would have included a robust search to identify
the evidence gap, as mentioned previously. The other
HTA trial (12/167/135) application stated how NICE
recommended the need for the research. The trial was
the initial attempt to address the research question using
an experimental method, designed to include a system-
atic review as part of the methodology (12/167/135:
Randomised controlled trial to examine the efficacy of e-
cigarettes compared with nicotine replacement therapy).
Primary outcomes
Eight trials (24 %) out of the 34 used a different pri-
mary outcome. For four trials it was unclear why a
different primary outcome had been chosen to that
used in the referenced systematic review. Two trials
established that the primary outcome used in the sys-
tematic review was not clinically important and the
remaining two trials were feasibility or pilot studies
(Table 3).
In addition to the above eight trials, 14 (41 %) trials
had a different primary outcome as each of these trials
referenced more than one review. It was unclear which
review was used to select the primary outcome.
We identified two studies from Cohort I and one study
from Cohort II which were first-in-class trials funded by
the NIHR HTA Programme. The justifications for these
trials being the first-in-class are listed in Additional file 3.
Discussion
This study replicated Jones et al. [8] study and further
explored the reasons why some trials did not reference a
systematic review. Our study shows that systematic re-
views were not referenced in five (11 %) of the 47 trials
funded in the period 2006–2008. All five trials had
plausible reasons for not referencing a systematic review.
In Cohort II all HTA trials funded during 2013 refer-
enced a systematic review. There appears to be two rea-
sons for not referencing a systematic review in Cohort I;
NICE TA were published prior to the trial being funded
and the HTA funding board being aware of the body of
evidence relating to that specific drug/intervention or
systematic review(s) had been identified but did not ad-
dress the proposed research question.
There is limited evidence about whether systematic re-
views are referenced or used in the design and planning
of randomised trials. One of the strengths of this study
is that it not only explored the reasons for non-reference
of a systematic review but also provided a broader over-
view of the evidence relating to the specific intervention
in the absence of reference to a systematic review. Sys-
tematic reviews are only used as a proxy measure to
understand if the existing evidence has been referred to.
Assumptions cannot be made about an application based
only on its referencing of a systematic review.
Additionally, a strength of our study was the develop-
ment of definitions for what constituted as a systematic
review and for different reasons for using a systematic
review in the design and planning of a trial. Building on
Jones’ previous work the current study was able to pilot
a classification system which was piloted by one reviewer
(SB) and quality assured by another reviewer (AY). Ap-
plying the classification to two cohorts has shown that
in some instances it is not possible or indeed plausible
to reference a systematic review. However, owing to the
interpretive nature of the classification system, this could
also be regarded as a limitation of this current study.
Previous research shows that little is known about
how existing evidence is used to inform the design and
reporting of randomised clinical trials. Goudie and col-
leagues [14] investigated whether authors of trials con-
sidered previous trials in their design and reported that
previous trial results were consulted in the design of just
37 % of current trials. Cooper et al. found that under
half (46 %) of responding authors of new research were
aware of relevant reviews when they designed their new
studies [15]. Compared to previous research our findings
demonstrate that funding applications to the NIHR HTA
Programme have a higher percentage of trials referen-
cing systematic reviews.
The HTA programme has two work streams (commis-
sioned and researcher-led) which the current study has
identified as an indicator to how different these streams
are when assessing the use and application of systematic
reviews during the application process. By extending
Jones et al. paper to include a clear definition of ‘system-
atic review’ to determine which reviews should be in-
cluded may have inadvertently resulted in differences
between our study and theirs However, by predefining a
description for each area of use these definitions can
now be piloted for similar research. The transparency of
using predefined definitions demonstrates the import-
ance of proposing the right research question and using
appropriate methods.
Using systematic reviews to inform trial design is im-
portant and it is recommended that research funders
make it a funding requirement to justify the need for
new research with existing evidence. The NIHR is now
committed to Adding Value in Research [16] to
maximize the potential impact of research it funds on
behalf of patients and the public. Chalmers and Glasziou
in their paper also recommended that research funders
and regulators demand that proposals for additional pri-
mary research are justified by systematic reviews evaluat-
ing what is already known [2]. The NIHR has now
included this in application guidelines for their research
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programmes to ensure that the research they fund an-
swers the right questions and has maximum impact.
Future research
The current study has shown that NIHR HTA trials use
systematic reviews where and when possible. There is a
need for better use of systematic reviews in the planning
and design of trials, with funders explicitly requesting in-
formation about what already exists and how their trial
design is based on existing evidence. To maximise the
benefit of trial results we now need to ensure that the pri-
mary outcome is fit for purpose.
Conclusions
Systematic reviews are referenced in NIHR HTA trials
wherever it is feasible to include a systematic review.
Ninety four percent of trials used one or more systematic
review(s) in their design and planning. The NIHR HTA
Programme requires evidence from systematic reviews be-
fore funding primary research and our study shows that
this is being implemented by applicants when they apply
for primary research funding. Systematic review authors
could maximise the impact of trial design by reporting pri-
mary outcomes that are relevant to the conduct of a trial.
Additional files
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Additional file 2: Reasons for not referencing and using a
systematic review. (PDF 201 kb)
Additional file 3: Justification for first-in-class trials. (PDF 19 kb)
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